At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Single-dose, Five-way Crossover Study Evaluating the Abuse Potential of Three Doses of NEURONTIN® Taken Orally in Healthy, Non-drug Dependent Participants With Sedative Drug Abuse Experience
In Brief
A Phase 4 clinical trial evaluating gabapentin 600 mg, gabapentin 1200 mg, and 3 other interventions for Abuse Potential. Completed, enrolled 52 participants across 1 site.
Detailed Summary
This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female participants with drug abuse experience with sedative drugs.
Study Details
Timeline
Interventions
participants will receive an oral dose of gabapentin 600 mg
participants will receive an oral dose of gabapentin 1200 mg
participants will receive an oral dose of gabapentin 1800 mg
participants will receive an oral dose of 20 mg dose of diazepam
participants will receive an oral dose of placebo